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Abstract
Background: Chemotherapy regimens for intrahepatic cholangiocarcinoma (ICC) and gallbladder ade-
nocarcinoma (GC) remain interchangeable; however, response rates are frequently suboptimal.
Biomarkers from ICC and GC patients were interrogated to identify actionable differences with poten-
tial therapeutic implications.
Methods: From 2009 to 2012, pathological specimens from 217 ICC and 28 GC patients referred to
Caris Life Sciences were evaluated. Specific testing by immunohistochemical analysis for 17 different
biomarkers was performed.
Results: In the collective cohort (n = 245), actionable targets included: 95% low thymidylate synthase
(TS), 82% low ribonucleotide reductase subunit M (RMM) 1 and 74% low excision repair cross
complementation group (ERCC) 1, indicating potential susceptibility to fluoropyrimidines/capecitabine,
gemcitabine and platinum agents, respectively. Additional targets included TOPO1 (53.3% high,
Irinotecan), MGMT (50.3% low, temozolomide), TOP2A (33% high, anthracyclines) and PGP (30.1%
low, taxanes). Subgroup analysis by tumour origin demonstrated a differential biomarker expression
pattern with a higher frequency of ICC tumours showing low levels of TS (99% versus 72%, P < 0.01),
and RRM1 (85% versus 64%, P = 0.02) when compared with GC. Conversely a greater frequency of
GC demonstrated high levels of TOPO1 (76% versus 50%, P = 0.02) versus ICC, indicating a potential
increased benefit from irinotecan.
Discussion: Differences in the molecular profiles between ICC and GC provide evidence that the two
are distinct diseases, requiring different treatment strategies to optimize a response.
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Introduction
Intrahepatic cholangiocarcinoma (ICC) and gallbladder adeno-
carcinoma (GC) are frequently considered a similar disease in
treatment planning. ICC is the second most common primary
malignant liver tumour and incidence rates have been increas-
ing in the United States and worldwide.1,2 Gallbladder adeno-
carcinoma, while rare among western countries, is the most
common malignancy of the biliary tract and shows a geograph-
ical variance, occurring more frequently in northern India,
Japan and Chile.3,4 For both ICC and GC, an R0 surgical resec-
tion is the only potentially curative treatment; however, both
diseases tend to be asymptomatic in the early stages and few
patients present early enough to be considered surgical candi-
dates.5,6
For many patients diagnosed with ICC and GC, chemotherapy
is the only treatment option. According to the National Compre-
hensive Cancer Network (NCCN), first-line regimens for both
ICC and GC are interchangeable, despite the two being
recognized as separate diseases. Accepted regimens include fluo-
ropyrimidine-based, gemcitabine-based, or gemcitabine/cisplatin
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combination therapy for advanced or unresectable disease.7
However, suboptimal response rates as evidenced by a median
survival of less than a year, underscore the need for more
effective treatment regimens.8,9
Research into the molecular pathogenesis of both ICC and
GC has revealed potential mechanisms contributing to
tumourigenesis. Epidermal growth factor receptor activation in
the setting of chronic inflammation, KRAS and IDH1 muta-
tions, as well as epigenetic and chromosomal abnormalities
have all been implicated in the development of ICC.10 While
GC has not been as thoroughly studied, mutations in KRAS,
p53, increased COX2, microsatellite instability and decreased
adhesion molecules have all been proposed to contribute
towards tumourigenesis.11 Recently, whole exome sequencing
of GC showed mutations in the ErbB pathway in 36% of
tumours analysed, and found the mutations correlated with a
poor prognosis.12 Despite these advances, much is still
unknown about the molecular profiles.
Many chemotherapeutic agents, however, have been exten-
sively studied across multiple tumour types, yielding insight
into their mechanisms of action, as well as the mechanisms of
susceptibility and resistance. Clinical susceptibility to fluoropy-
rimidines is associated with a low expression of thymidylate
synthase (TS),13 susceptibility to gemcitabine is associated with
low expression levels of ribonucleotide reductase subunit M1
(RRM1) 14 and susceptibility to platinum agents, such as cis-
platin, are associated with low expression of excision repair
cross complementation group 1 (ERCC1).15 The use of all
three of these drugs is recommended in advanced ICC and
GC. Thus, information about the expression of TS, RRM1 and
ERCC1 has a potential theranostic value.
Biomarker analysis of actionable targets known to convey
susceptibility to specific drugs has been purported to be an
effective method of tailoring existing chemotherapeutic agents
to exploit the specific weaknesses in individual tumours.16,17
Studies have demonstrated that molecular profile-guided thera-
pies can provide improved response rates across multiple
tumour types.18 This study sought to differentiate the molecu-
lar profiles of ICC and GC by a panel of biomarkers to evalu-
ate the potential efficacy of current chemotherapy regimens
and potentially refine current treatment strategies.
Patients and methods
From 2009 to 2012, pathological specimens from 217 ICC and
28 GC patients were referred to Caris Life Sciences, a commer-
cial referral diagnostic laboratory, for molecular profiling
aimed at providing theranostic information. The diagnoses and
tissue samples were collected from referring physicians accord-
ing to pathology and clinical history. This de-identified data
were obtained directly from Caris Life Sciences. As the data
was de-identified, patient consent was not required.
Immunohistochemistry
Specific testing by Immunohistochemistry (IHC) was per-
formed for 17 different biomarkers using the following anti-
bodies: AR (AR441/AR318), BCRP (6D171), cKIT (polyclonal),
ERCC1 (8F1), ER (SP1), Her2 (4B5), MGMT (MT23.3),
MRP1 (33A6), PGP (C494), PR (1E2/100), PTEN (6H2.1),
RRM1 (polyclonal), SPARC monoclonal (122511), SPARC
(polyclonal), TOPO1 (1D6), TOPO2A (3F6) and TS (TS106/
4H4B1). IHC analysis was performed on formalin-fixed paraf-
fin-embedded tumour samples using commercially available
detection kits, automated staining techniques (Benchmark XT;
Ventana, Tucson, AZ, USA; and AutostainerLink 48; Dako,
Carpinteria, CA, USA) in a CLIA/CAP certified, ISO validated
lab (Caris Life Sciences, Phoenix, AZ, USA). Staining intensity
was scored 0, 1+, 2+ or 3+, and the percentage of stained cells
(0–100%) was assessed by board-certified pathologists. Results
were then categorized into positive or negative by defined
thresholds specific to each marker based on published evidence
(Supporting information).
Institutional Review Board
We obtained Institutional Review Board approval to retrospec-
tively review and analyse the data collected from the pathologi-
cal specimens described above.
Statistical analysis
Categorical variables were described as totals and frequencies.
Comparison between subgroups was analysed using a two-
sided, Fisher’s exact test for categorical data and a two-sided
Mann–Whitney U-test for continuous variables. Alpha was set
at 0.05.
Results
In total, 245 tissue samples were analysed; 217 IHC and 28
GC. The median age of the total cohort was 58 years, with a
slight female preponderance (n = 133, 54%). By subgroup, the
median age for ICC patients was 58 years, and 59 years for GC
patients (P = 0.373). Both subgroups showed a female prepon-
derance, however, it was much more pronounced in the GC
subgroup (n = 20, 71%) as compared with the ICC subgroup
(n = 113, 52%; P = 0.069).
Biomarker analysis of actionable targets
IHC analysis of biomarkers associated with first-line
chemotherapy agents among the total cohort found TS expres-
sion to be low in 96% (fluoropyrimidines), low RRM1 expres-
sion in 82% (gemcitabine) and low ERCC1 expression in 74%
(Cisplatin, Table 1). Additional non-NCCN compendium
agents and their associated biomarkers were also analysed.
Among the total cohort, potential susceptibility to irinotecan,
temozolomide, nab-paclitaxel and epirubicin occurred at lower
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frequencies (Table 1). Biomarkers associated with susceptibility
to these drugs demonstrated an elevation in TOPO1 (irinote-
can) expression in 53%, decreased expression of MGMT
(temozolomide) in 50%, increased SPARC (nab-paclitaxel) in
34% and increased expression of TOP2A (epirubicin) in 30%
(Fig. 1).
Subgroup analysis by tumour origin
When comparing the molecular profiles based on site of origin,
six of the 17 biomarkers demonstrated a differential expression
pattern (Table 2). In particular, TS (99% versus 72%; P <
0.01), RRM1 (85% versus 64%; P = 0.021) and MRP1 (33%
versus 9%; P = 0.024) were all shown to be actionable more
frequently in ICC, which indicates a greater potential benefit
from fluoropyrimidines, gemcitabine and etoposide, respec-
tively. Conversely, TOPO1 (76% versus 50%; P = 0.018) and
PTEN (36% versus 16%; P = 0.027) were shown to be action-
able more frequently in GC indicating a greater potential bene-
fit from irinotecan and erlotnib, respectively.
Discussion
The NCCN currently recommends fluoropyrimidine-based,
gemcitabine-based or gemcitabine/cisplatin combination ther-
apy for the treatment of advanced ICC and GC. However, the
use of gemcitabine/cisplatin therapy is the only treatment
option backed by category 1 evidence. This was based primar-
ily on the findings of a phase III clinical trial, which demon-
strated that gemcitabine/cisplatin increased median progression-
free survival from 5 to 8 months for advanced biliary tract
cancers, compared with gemcitabine alone.19 Among patients
included in the study were those with ICC or GC, which resulted
in the dual agent regimen being applied to either tumour type.
Consistent with these recommendations, we found that the
three biomarkers most frequently actionable across the entire
cohort were TS (96%), RRM1 (82%) and ERCC1 (74%), infer-
ring susceptibility to fluoropyrimidines, gemcitabine and plat-
inum agents, and supporting their use as first-line agents.
Supporting evidence for the use of these agents in the treat-
ment of ICC is even stronger, as TS, RRM1 and ERCC1 are
were found to be actionable in 99%, 85% and 75% of samples.
Furthermore, low ERCC1 is associated with susceptibility to
platinum-based agents, and the high frequency that ERCC1
was actionable further supports the efficacy of gemcitabine/
oxaliplatin, which has been demonstrated by several phase II
clinical trials.20,21
However, when compared with the ICC subgroup, TS,
RRM1 and ERCC1 were actionable at a lower frequency among
the GC samples. TS was actionable in 72%, and both RRM1
and ERCC1 were actionable in 64% of samples each, suggest-
ing that there is a large subgroup of patients who may not
respond to the recommended first-line therapies. Furthermore,
the most frequently actionable target for GC is TOPO1 (76%)
associated with a susceptibility to irinotecan22 suggesting that
its use in the treatment of GC could prove beneficial and
should be investigated. Indeed there are currently several phase
II clinical trials that are looking into its use in various combi-
nations to treat advanced gallbladder and biliary tract cancers
(SCH01, GAMBIT201201).
In the entire cohort, actionable targets associated with non-
NCCN compendium drugs include MGMT (50%) and SPARC
monoclonal (34%) which have been associated with suscepti-
bility to temozolomide23 and nab-paclitaxel.24 While we did
not find these biomarkers to be actionable as frequently as the
first-line agents, they suggest alternative treatment options that
should be further explored in a clinical setting. In fact, drugs
associated with eight of the 17 biomarkers analysed are cur-
rently being investigated, in various combinations, in ongoing
clinical trials.
Comparative analysis by tumour type provides evidence that
ICC and GC are molecularly distinct diseases and merit different
treatments. We found a differential expression pattern in the six
of the 17 biomarkers analysed. TS (99% versus 72%; P < 0.01)
as well as RRM1 (85% versus 64%; P = 0.021) were significantly
decreased in GC as compared with the ICC. The suggested
potential decrease in tumour response to fluoropyrimidines and
gemcitabine, in patients with GC, is particularly noteworthy as
these drugs represent two of the three first-line drugs.
The differences in the molecular profiles of ICC and GC
suggest that response rates to the first-line agent can be vari-
able and supports a more targeted therapeutic approach to
Table 1 The frequency of actionable targets along with associated
therapies in the total cohort (n = 245)
Target biomarker % N Associated agent
TS () 96 199 Fluoropyrimidine, capecitabine
RRM1 () 82 197 Gemcitabine
ERCC1 () 74 197 Cisplatin
TOPO1 (+) 53 199 Irinotecan
MGMT () 50 203 Temozolomide
SPARC Monoclonal (+) 34 213 Nab-paclitaxel
TOP2A (+) 33 191 Epirubicin
PGP () 30 176 Taxane
MRP1 () 30 177 Etoposide
SPARC Polyclonal (+) 19 213 Nab-paclitaxel
PTEN (+) 19 209 Erlotnib, Cetuximab
PR (+) 6 201 Hormonal therapy
BCRP () 5 58 Doxorubicin
C-KIT (+) 4 175 Sorafenib, sunitinib, imatinib
Her2/Neu (+) 2 207 Trastuzumab
AR (+) 1 197 Hormonal therapy
ER (+) 1 203 Hormonal therapy
() = decreased expression, (+) = increased expression.
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these diseases. The concept of using a tumour’s specific molec-
ular characteristics is being used with increased frequency.
Molecular profiling has been used to guide treatment in breast
cancer25 and to identify site-specific therapy in carcinoma of
an unknown primary site.26 Von Hoff et al. used molecular
profiling to guide the treatment of 66 patients with refractory
metastatic cancer and found that 47% of patients showed some
reduction in tumour size. Furthermore, an increase in the pro-
gression-free survival (PFS) of 30% compared with the PFS of
the most recent failed regimen was demonstrated in 20 patients
(27% of the entire cohort) – five of whom had GI cancer, one
of which was cholangiocarcinoma.18 Currently, a phase II clini-
cal trial is investigating the use of molecular profiling to
prospectively guide neoadjuvant and adjuvant therapy in
patients with pancreatic cancer (NCT01726582).
This study has several limitations; first, this was a retrospec-
tive analysis of de-identified data compiled from tissue samples
sent for biomarker analysis. Consequently, clinical and disease
related data were obtained solely from referring physicians and
was verified by board-certified pathologists at Caris, and clinical
information regarding prior therapy, decisions that resulted, or
final outcomes are unknown. Obtaining prospective data is cur-
rently the goal of an ongoing study by Caris Life Sciences. In
addition, the number of available GC samples was limited and
may have affected the precision of the analysis. While there is
growing evidence to suggest that biomarker analysis can be used
to identify actionable targets for treatment, to date, there are no
large, prospective studies proving this for ICC or GC. Addition-
ally, our analysis of the molecular profiles of these two diseases
was based solely on immunohistochemical data and did not
evaluate other methods of molecular profiling such as Sanger or
NextGen sequencing. Lastly, while the present study demon-
strated a high percentage of samples possessing a molecular
profile consistent with susceptibility to first-line agents, the
poor response rates noted in clinical trials to these drugs,
underscores additional factors such as the tumour microenvi-
ronment as having a potential role in affecting drug efficacy.27
In conclusion, ICC and GC continue to carry a poor prog-
nosis, thereby highlighting the need for more effective
treatment regimens. The use of molecular profiling to guide
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Figure 1 The overall frequency of actionable targets with potential susceptibility to established chemotherapeutic agents among all
tumours tested by immunohistochemistry (n = 245)
Table 2 Biomarker comparison of intrahepatic cholangiocarcinoma and gallbladder cancer by immunohistochemistry
Target Biomarker Associated agent ICC (%)
n = 217
GC (%)
n = 28
P-value Increased benefit for
TS Fluoropyrimidines, capecitabine 99 72 <0.01 ICC
RRM1 Gemcitabine 85 64 0.021 ICC
MRP1 Etoposide 33 9 0.024 ICC
TOPO1 Irinotecan 50 76 0.018 GC
PTEN Erlotnib, Cetuximab 16 36 0.027 GC
HER2/Neu Trastuzumab 1 12.5 <0.01 GC
ICC, intrahepatic cholangiocarcinoma; GC, gallbladder adenocarcinoma.
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treatment has shown promising results in other tumour types
and warrants further investigation. While our analysis supports
the use of fluoropyrimidines, gemcitabine and cisplatin as first-
line agents to treat ICC and GC, we also identified agents, such
as irinotecan, that could be beneficial in subsets of patients
unresponsive to first-line drugs. The molecular characteristics
described, in addition to the differential expression pattern
found between ICC and GC provides compelling evidence that
future investigations should approach these diseases indepen-
dently.
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Supporting information
Additional Supporting Information may be found in the online version of this
article:
Table S1. Thresholds to categorize the immunohistochemical staining as
high (positive) or low (negative).
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